Merck Canada to bring portfolio of biosimilars to the market
As part of the previously-announced agreement between US pharma giant Merck & Co (NYSE: MRK) and Samsung Bioepis, Merck Canada announced today that it is preparing to bring to market a diversified portfolio of biosimilar medicines in Canada over the coming years.
Among the biosimilars being developed under the collaborations between Merck and Bioepis, a joint venture between Korea’s largest conglomerate Samsung’s Samsung Biologics unit and US biotech firm Biogen Idec (Nasdaq: BIIB), is Brenzys (etanercept), a biosimilar of the immunology drug Enbrel from Amgen. Brenzys has so far been approved in South Korea (The Pharma Letter September 8) and is under review by the European Medicines Agency.
Working together to establish a landscape of biosimilars in Canada
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze